A5093237374- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Acute Myeloid Leukemia Research
- Social Media in Health Education
- Computational Drug Discovery Methods
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Tumors and Oncological Cases
- Polyomavirus and related diseases
- Melanoma and MAPK Pathways
Novartis (Switzerland)
2023-2024
Abstract Steroid-refractory chronic graft-versus-host disease (cGvHD) is associated with significant morbidity and mortality, ruxolitinib being the first drug approved for its treatment. We retrospectively analyzed safety efficacy of treatment cGvHD at our center between 07/2015 12/2022 identified 48 patients receiving as second (18/48) or advanced (30/48) line. Ruxolitinib was started on median day 340 (range 119–595) after onset; duration administration 176 (range, 79–294) days 16/48...
The ruxolitinib compassionate use (CU) program offered to patients ≥2 years of age with confirmed steroid-resistant acute or chronic graft-versus-host disease (aGvHD and cGvHD, respectively). Data from 1180 (n = 775, 370 35 aGvHD, non-specified GvHD, respectively) were analyzed. Most had severe cGvHD (56%) stage III/IV aGvHD (70%) previously received corticosteroids ( > 80%); was requested primarily as a second-/third-line option. Patients <12 ≥12 old most often the recommended doses (5 mg...
Graft-versus-host disease (GVHD) is the major cause of short- and long-term morbidity mortality after allogeneic hematopoietic stem cell transplantation. Treatment options beyond corticosteroid therapy remain limited, prolonged treatment often leads to impaired quality life (QoL). A better understanding needs experiences patients with GVHD required improve patient care.The aim this study explore different social media (SM) channels for gathering analyzing other stakeholders across 14...
BackgroundThe Kaiku Health platform is an electronic patient-reported outcome (ePRO) system aimed at monitoring symptoms and quality of life (QoL) among cancer patients. ePRO systems allow timely interventions to symptoms, which has been shown improve treatment adherence, QoL, survival. We examined QoL in stage III–IV melanoma patients using the module. Additionally, we evaluated prediction symptom onset or continuation a machine learning (ML) model.MethodsPatients ≥18 years old with...
<sec> <title>BACKGROUND</title> Graft-versus-host disease (GVHD) is the major cause of short- and long-term morbidity mortality after allogeneic hematopoietic stem cell transplantation. Treatment options beyond corticosteroid therapy remain limited, prolonged treatment often leads to impaired quality life (QoL). A better understanding needs experiences patients with GVHD required improve patient care. </sec> <title>OBJECTIVE</title> The aim this study explore different social media (SM)...